Trial Search Results

HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)

The purpose of this study is to demonstrate the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact (HeartLight) in the treatment of atrial fibrillation by creating electrical isolation of the pulmonary veins.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

CardioFocus

Intervention(s):

  • Device: EAS-AC (HeartLight)
  • Procedure: Control Arm Ablation

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - 18 to 75 years.

   - paroxysmal atrial fibrillation

   - failure of at least one AAD

   - others

Exclusion Criteria:

   - overall good health as established by multiple criteria

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Gerri O'Riordan
650-725-5597
Not Recruiting